About the Industry Liaison Forum


  • Goals & Objectives
  • Who we are
  • History

Goal

Promote and facilitate the full contribution of the biomedical industry to the global HIV response.


Specific objectives

The work of the ILF includes three main objectives (axes), taking advantage of this unique forum to highlight the perspective of the HIV biomedical industry in the context of the global HIV response.


  • Collaborative platform
    Maintain a multi-stakeholder collaboration platform including a broad industry contribution

    The ILF is a unique platform that brings together, through its advisory group, not only a diverse cross-section of the HIV biomedical industry, but also several key stakeholders involved in the global HIV response, including academia, regulatory and normative agencies, procurement and implementing organizations, governmental and intergovernmental organizations and civil society (including the community of people living with HIV – PLHIV). Industry is brought to the ILF outside of commercial interests and in this multi-stakeholder platform, which aims to remove some of the existing silos to catalyse collaboration across sectors. Another aspect of the ILF work relates to promoting global health and IAS values to biomedical industry stakeholders with no prior history of involvement beyond commercial interest.
     

  • Paediatric HIV
    Fast track the development, marketing, supply, uptake and utilization of paediatric HIV diagnostics and medicines (including the most-needed paediatric ARVs)

    There are many challenges in paediatric HIV. For making priority paediatric ARV formulations available, these include technical difficulties in developing child-friendly formulations, absence of an attractive market for industry, and difficulty including industry in the development of normative guidance. There is a need to explore alternative models of collaborations and innovative financing mechanisms building on existing regulatory processes, optimizing investments in paediatric ARVs and enabling the sustainable development of prioritized products. Challenges also exist around paediatric HIV diagnostics (e.g., with regards to clinical trials of early infant diagnosis devices). Since 2013, the ILF (often in collaboration with CIPHER) has catalysed multi-stakeholder dialogues to raise awareness of and brainstorm on approaches to address some of the key challenges around paediatric HIV, in particular paediatric ARVs.

    The ILF is a key partner of the Paediatric HIV Treatment Initiative (PHTI, a collaboration of UNITAID, CHAI, DNDi, and MPP which includes the WHO as a technical partner). The ILF also collaborates closely with the Global Pediatric Antiretroviral Commitment-to-Action (CTA, composed of PEPFAR, PHTI and the Global Fund).
     

  • Regulatory affairs
    Fast track regulatory approval of quality HIV prevention, diagnostics and medicines to ensure timely access by populations most in need

    Varying and overlapping regulatory requirements across countries (including national regulatory agencies and WHO Prequalification) are often not transparent and frequently require companies to conduct additional clinical trials and file multiple applications. These lead to increases in associated costs and, most importantly, increases in delays before new diagnostic tools and medicines can be registered and sold in‑country, thereby ultimately delaying access by populations most in need. Simplification and harmonization of regulatory requirements therefore represents an important area with the potential to fast track access to better prevention devices, diagnostics and medicines.

ILF Advisory Group

The IAS Secretariat recognizes the value of a multi-stakeholder approach with a strong advisory group to guide our efforts. The ILF Advisory Group is composed of representatives from industry, together with non-industry representatives knowledgeable in the topics covered by the ILF and other aspects of its work. The ILF Advisory Group is co-chaired by an industry representative and an IAS Governing Council member. The ILF Advisory Group not only allows the IAS to interact with industry, but it also allows non-industry and industry stakeholders to interact together, a hallmark of the ILF since its inception. Indeed, only through a multi-stakeholder approach can critical gaps in HIV research and implementation strategies be identified and solutions developed for addressing them.

ILF Advisory Group members are listed below, additional details (i.e. biographies and pictures) are available on this page.

Since 2014 Kenneth Mayer The Fenway Institute USA
Since 2014 Manuel Gonçalves ViiV Healthcare UK
See the list of previous ILF Advisory Group Co-Chairs
Since 2015 Brent Allan Living Positive Victoria Australia
Since 2014 Martin Auton Global Fund Switzerland
Since 2014 John Bannister Omega Diagnostics UK
Since 2013 Linda-Gail Bekker University of Cape Town South Africa
Since 2014 Chris Beyrer Johns Hopkins University USA
Since 2015 Duncan Blair Alere Switzerland
Since 2016 Samuel (Tony) Boova Beckman Coulter USA
Since 2010 Celia Christie-Samuels University of the West Indies Jamaica
Since 2014 Gavin Cloherty Abbott USA
Since 2014 Elliot Cowan Partners in Diagnostics USA
Since 2014 Colleen Daniels Stop TB Partnership Switzerland
Since 2017 Boniface Dongmo Nguimfack WHO Switzerland
Since 2015 Philippe Duneton UNITAID Switzerland
Since 2016 Samantha Giangregorio Sysmex Corporation South Africa
Since 2014 Manuel Gonçalves ViiV Healthcare UK
Since 2009 Catherine Hankins Amsterdam Institute for Global Health and Development The Netherlands
Since 2009 Nicholas Hellmann Elizabeth Glaser Pediatric AIDS Foundation USA
Since 2015 Philippe Jacon Cepheid France
Since 2016 Sharadd Jain Cipla India
Since 2017 Mukul Jerath Lupin India
Since 2015 Sandeep Juneja Medicines Patent Pool Switzerland
Since 2009 Sandra Lehrman Merck USA
Since 2014 Kenneth Mayer The Fenway Institute USA
Since 2012 Perry Mohammed Janssen UK
Since 2014 Jeffrey Murray U.S. Food and Drug Administration USA
Since 2012 Rahab Mwaniki National Empowerment Network of People Living with HIV/AIDS Kenya
Since 2017 Ellen Paxinos Roche Molecular Systems USA
Since 2014 Jürgen Rockstroh University of Bonn Germany
Since 2006 James Rooney Gilead Sciences USA
Since 2015 Mauro Schechter Universidade Federal do Rio de Janeiro Brazil
Since 2016 Matthias Stahl WHO Switzerland
Since 2015 Wim Vandevelde Global Network of People Living with HIV South Africa
Since 2015 Denise van Dijk Female Health Company The Netherlands
Since 2017 Colleen Wegzyn AbbVie USA
See the list of previous ILF Advisory Group members
Sebastien Morin ILF Research Officer Switzerland
Owen Ryan IAS Executive Director Switzerland

Established by the International AIDS Society’s Past President Joep Lange in 2001, the Industry Liaison Forum (ILF) has been a multi-stakeholder platform consisting of industry, community, academia, normative agencies and international organizations that have a mission to accelerate scientifically promising, ethical HIV research in resource-limited countries, with a particular focus on the roles and responsibilities of industry as sponsors and supporters of research. It emerged from a shared need to tackle a number of ethical issues related to conducting research in resource-limited settings (RLS). The ILF convened and mobilized various stakeholders to address complex and inter-related issues and identify overlooked research issues. It was also based on the recognition of the roles and responsibilities of pharmaceutical and diagnostics companies as partners in the fight against HIV.



The ILF has been governed by an advisory group that was co-chaired by an IAS Governing Council (GC) member and an industry representative. Members of the ILF Advisory Group consisted of scientific representatives of industry, four IAS GC members, two community representatives, and up to four experts from international organizations, UN agencies or academia with expertise in the strategic priorities of the ILF.

Initially, the ILF promoted dialogue around key issues in HIV research in RLS, including considerations around post-trial care provision, as well as the quality of generic drugs (as outlined in the 2002-2003 progress report, Clinical Research in the Developing World Towards a Consensus Framework: Focus on Provision of Post-Trial Care). Pre-exposure prophylaxis (PrEP) officially became a priority of the ILF as part of its Strategic Plan 2006-2008, which emphasized the need for consultation on the ethical considerations around antiretroviral (ARV)-based prevention research.

The value of the ILF was recognized in an evaluation performed in 2007 in which respondents demonstrated strong support for the ILF as a vehicle for bringing together key stakeholders to address specific scientific and operational issues related to conducting research in RLS and the work undertaken around PrEP. There was also a strong desire from the group for the ILF to become more “action oriented and outcomes focused” while establishing “more tangible objectives/outcomes” for its work. Respondents also identified the need to broaden representation in meetings, with more government participation and increased engagement with researchers from low- and middle-income countries.

In preparation for its Strategic Plan 2008-2011, following a priority-setting exercise, the ILF Advisory Group decided to focus on increasing the number of HIV clinical research projects in RLS that industry is involved with and that address the needs of women and children, populations that were deemed to have been overlooked in the global response.

One of the tangible deliverables during the period of the Strategic Plan 2008-2011 was the multi-stakeholder consultation that resulted in a Consensus Statement endorsed by 16 organizations. Several related publications were also produced in this context: an ILF Environmental Scan, an article in BMC Public Health, and two articles in JAIDS in 2011 and 2012. The importance of women and children and the foresight of the ILF’s focus on these issues were affirmed in 2011 at the United Nations High Level Meeting on AIDS in New York that placed special emphasis on the elimination of paediatric HIV and on the health of mothers.

In 2011, the ILF Advisory Group engaged in another priority-setting exercise for its Strategic Plan 2012-2014 and decided to maintain its focus on women and children. Challenges with regard to paediatric treatment options and optimal strategies for addressing women’s needs were considered overlooked areas in which industry, with other stakeholders, could play an important role. It furthermore expanded its area of influence by including challenges related to resistance, diagnostics, monitoring and other barriers.

With this strategic plan, the ILF has supported research and other strategies to: enhance treatment management; scale up prevention of mother-to-child transmission (PMTCT) programmes; improve prevention and treatment access and outcomes for vulnerable populations of women and children; optimize the potential of PrEP and other chemoprevention interventions; and promote best practices in public health policy and delivery.

In 2013, the ILF organized several events, including an Industry Roundtable on Paediatric ARVs entitled “Paediatric antiretrovirals: The barriers to and solutions for improved access to optimal drugs in resource-limited settings” (meeting report available online), the first of a new series of ILF Thematic Roundtables. The meeting was attended by 13 ARV manufacturers and 12 international organizations and highlighted key issues while giving rise to constructive ideas.

In 2013, the ILF also embarked on a process of rethinking itself. The entire ILF Advisory Group was involved and the work was expanded to rethinking the various ways in which the IAS had interacted with industry in the past and how it could do so in the future. The ILF is now evolving into playing a more central role within the IAS, towards building and strengthening synergy with industry in the fight against the HIV/AIDS epidemics.

The year 2014 saw the ILF broaden its constructive interactions with industry and other stakeholders. This revisited ILF builds on the successes of the ILF at embracing a multi-stakeholder approach, but in an expanded context and with an enhanced portfolio of impactful activities.

 

Background Documents



ILF Advisory Group Organigram
(Last updated on 12 May 2016)


ILF Advisory Group
Terms of Reference

(Last updated on 26 August 2015)


ILF Corporate Partnership Programme
(Last updated on 27 January 2015)